PlexinD1-Targeted Nanoprobe for Early Plaque Imaging
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current imaging methods for atherosclerotic plaques lack the ability to provide early warning and continuous dynamic monitoring, with existing multi-modal imaging techniques having limitations such as unsuitable target molecules, limited sensitivity and spatial resolution, and complex operations.
Innovation Solution
A multi-modal molecular imaging nanoprobe, Fe3O4-A12-Cy7, specifically targeting PlexinD1, combined with FLI/MPI/CTA for high sensitivity and spatial resolution, enabling early warning and dynamic monitoring of atherosclerotic plaques.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional imaging methods (CTA, ultrasound, MRI, PET, SPECT) are used for plaque identification, then non-invasive imaging is achieved, but sensitivity and spatial resolution are limited
Solution Approach 1:
The patent combines multiple imaging modalities (FLI, MPI, CTA) into a single integrated nanoprobe system. The Fe3O4-A12-Cy7 nanoprobe simultaneously provides fluorescence imaging, magnetic particle imaging, and CT angiography capabilities, merging the advantages of different imaging methods while reducing overall system complexity through a unified platform
Solution Approach 2:
The nanoprobe Fe3O4-A12-Cy7 serves multiple functions: it acts as a contrast agent for MRI, a tracer for PET, a fluorescence marker, and a CT contrast medium. This multi-functional design allows a single probe to address various imaging needs simultaneously, improving sensitivity and spatial resolution without requiring multiple separate agents
2Measurement precision
If invasive imaging methods (angioscopy, OCT, IVIS) are used to observe plaque components, then detailed component observation is achieved, but continuous dynamic monitoring becomes difficult
Solution Approach 1:
The nanoprobe is designed to be self-retaining within the atherosclerotic plaque through specific binding to PlexinD1 receptors. This self-anchoring capability allows the probe to remain in place for extended periods, enabling continuous dynamic monitoring without requiring repeated invasive procedures or sacrificing the animal model
Solution Approach 2:
The probe is injected systemically before the atherosclerotic plaque fully develops, allowing early detection and continuous monitoring throughout the disease progression. The preliminary systemic circulation ensures the probe reaches the plaque site before significant changes occur, enabling early warning and longitudinal studies
3Measurement precision
If existing multi-modal imaging probes are used, then imaging sensitivity is improved, but operation complexity increases
Solution Approach 1:
The nanoprobe is segmented into distinct functional components: Fe3O4 core for MRI contrast, A12 antibody for specific targeting, and Cy7 fluorophore for fluorescence imaging. This segmentation allows each component to be optimized independently while simplifying the overall operation, as the probe is administered as a single unit that automatically performs all imaging functions
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The nanoprobe achieves high sensitivity and spatial resolution, allowing for accurate, continuous, and 3D stereoscopic imaging of atherosclerotic plaques, supporting basic research on plaque progression and therapeutic efficacy.
Implementation Method 1
As a magnetic resonance enhancer, iron oxide nanoparticles have small particle size and strong penetrating ability. They can significantly shorten the T2 relaxation time of MRI and thus improve the signal-to-noise ratio
Implementation Method 2
a multi-modal molecular imaging nanoprobe for early warning and dynamic monitoring of atherosclerotic plaques, and the nanoprobe is Fe3O4-A12-Cy7
Data Source
AI summary
The present invention belongs to the technical field of fluorescence detection, and specifically relates to a multi-modal molecular imaging nanoprobe for early warning and dynamic monitoring of atherosclerotic plaques and the use thereof. The multi-modal molecular imaging nanoprobe for early warning and dynamic monitoring of atherosclerotic plaques is Fe3O4-A12-Cy7. The probe of the present invention is Fe3O4-A12-Cy7, wherein protein A12 is a single-domain antibody that can specifically bind to PlexinD1, that is, probe Fe3O4-A12-Cy7 can specifically bind to PlexinD1, thus achieving the optimization of the target. According to the present invention, FLI/MPI/CTA is fused to form multi-modal imaging. The multi-modal imaging has the advantages of a high sensitivity and a high spatial resolution, can realize early warning and dynamic monitoring of atherosclerotic plaques, and can also visually reflect 3D stereoscopic imaging, thereby providing theoretical support and technical support for basic research.